Skip to content

Effect of Bloodletting at Shaoshang and Shangyang Points on Body Temperature and Prognosis of Severe Community-acquired Senile Pneumonia

Effect of Bloodletting at Shaoshang and Shangyang Points on Body Temperature and Prognosis of Severe Community-acquired Senile Pneumonia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005113
Enrollment
Unknown
Registered
2021-07-30
Start date
2019-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe community-acquired elderly pneumonia

Interventions

Sponsors

Tongzhou District, Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients who attended the intensive care unit of the East District of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine from 2019 to 2020 who met the severe community-acquired elderly pneumonia and had fever (body temperature greater than 38.5?); 2. Aged > 65 years old; 3. The patient or his immediate family members gave informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. The investigator judges that it cannot be completed or is unsuitable to participate in the study (it is expected to die within 48 hours, and the patient refuses to actively treat); 2. Lack of thumb or index finger; 3. Severe hospital-acquired pneumonia; 4. Ventilator-related severe pneumonia; 5. Patients with infections other than lung infections, such as abdominal cavity infections, urinary tract infections, and intracranial infections; 6. Patients with severe coagulopathy; 7. Patients who have been treated with hormones, immunosuppressants and other drugs for a long time; 8. Malignant tumors, liver cirrhosis, chronic renal failure (uremia), blood system diseases, immune system diseases, acquired immune system diseases (HIV) and other serious basic diseases; 9. Women during pregnancy or lactation; 10. Participate in other clinical trials within 30 days.

Design outcomes

Primary

MeasureTime frame
body temperature;Breathe;awareness;

Countries

China

Contacts

Public ContactZhang Qing
15901116302@163.com+86 15901116302

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026